fashion -WSS

fashion

author：comprehensive 2025-10-01 11:43:57 - browse：879

An AstraZeneca sign at ESMO in Madrid. — An AstraZeneca ad at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months.

On Monday, data presented here from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.

The trial, detailed here in a prime session at the annual meeting of the European Society for Medical Oncology, is testing a therapy called datopotamab deruxtecan, or Dato-DXd, in advanced or metastatic non-small cell lung cancer in patients who already tried at least first-line treatments. Patients were randomized to either receive chemotherapy or Dato-DXd, which AstraZeneca is developing with Daiichi Sankyo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Supreme Court mifepristone arguments center on docs' right to sue

focus

WSS

Hospitals, health systems can help patients avoid medical debt

Marc Tessier

An outrageous hospital charge: I paid $710 for an hour of babysitting

Hospitals, health systems can help patients avoid medical debt

Behind warning on Apellis’s eye drug lies a conflict of interest

Trump lawyers meet with special counsel in Jan. 6 case as potential indictment looms

leisure time

fashion

knowledge

BioMarin wins approval for gene therapy to treat hemophilia A

Readout LOUD podcast: mifepristone case, GLP

State Dept. review finds Biden bears some blame for Afghanistan failures

Interest rates are at a 22

Walensky prepares to leave CDC — and Congress — behind

There's no autism epidemic. It's an autism diagnosis epidemic

Supreme Court strikes down use of affirmative action

Patient advocates debate FDA's accelerated approval process

Hepatitis C has a cure — but many Americans still lack access to it

Marc Tessier

entertainment

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

VC firm RA Capital starts a new synthetic biology incubator

Biden to sign 'historic' executive order on how US military handles sexual assault cases

Abortion pill case raises question: who can sue the FDA?

Ending health disparities requires full federal government, panel says

Stoke drug shows lower activity against childhood epilepsy

Wikipedia

focus

explore

entertainment